Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021

SELL
$0.7 - $1.58 $21,000 - $47,400
-30,000 Closed
0 $0
Q3 2020

Nov 04, 2020

BUY
$0.61 - $1.6 $18,300 - $48,000
30,000 New
30,000 $22,000

Others Institutions Holding OTLK

About Outlook Therapeutics, Inc.


  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $364M
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.